Details of Disease

General Information of Disease (ID: DISFK2QT)

Disease Name Thyroid gland follicular carcinoma
Synonyms
follicular adenocarcinoma; follicular adenocarcinoma, well differentiated (morphologic abnormality); thyroid gland adenocarcinoma; follicular adenocarcinoma (morphologic abnormality); follicular adenocarcinoma, well differentiated; follicular cancer of thyroid gland; thyroid gland follicular cancer; well-differentiated follicular carcinoma; follicular cancer of thyroid; follicular cancer of the thyroid gland; follicular cancer of the thyroid; follicular carcinoma; carcinoma, follicular cell, malignant; follicular thyroid gland carcinoma; follicular carcinoma of the thyroid; follicular thyroid carcinoma; follicular carcinoma of thyroid gland; follicular carcinoma of the thyroid gland; follicular carcinoma of thyroid; thyroid follicle carcinoma; follicular thyroid cancer; carcinoma of thyroid follicle; thyroid follicular carcinoma; well-differentiated follicular adenocarcinoma; thyroid gland follicular carcinoma
Definition
A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. The nuclear features which characterize the thyroid gland papillary carcinoma are absent. Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers. Clinically, it usually presents as a solitary mass in the thyroid gland. It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels. Diagnostic procedures include thyroid ultrasound and fine needle biopsy.
Disease Hierarchy
DIS1V20Y: Differentiated thyroid carcinoma
DISEZVFP: Thyroid gland adenocarcinoma
DISH9F1N: Carcinoma
DISFK2QT: Thyroid gland follicular carcinoma
Disease Identifiers
MONDO ID
MONDO_0005034
MESH ID
D018263
UMLS CUI
C0206682
MedGen ID
64630
HPO ID
HP:0006731
SNOMED CT ID
255028004

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Lenvatinib DMB1IU4 Approved Small molecular drug [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 27 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CRY2 TTAO58M Limited Altered Expression [2]
HRAS TT28ZON Limited Genetic Variation [3]
PTEN TTXJ3W7 Limited Biomarker [4]
TICAM1 TT2GQT6 Limited Genetic Variation [5]
TSHR TT6NYJA Limited Biomarker [6]
KLB TTARBVH Disputed Biomarker [7]
DPEP1 TTYUENF moderate Altered Expression [8]
RAPGEF4 TTOS63B moderate Biomarker [9]
ST8SIA4 TTDP8YM moderate Altered Expression [10]
AQP7 TTNGCRK Strong Biomarker [11]
DIO1 TTU3X26 Strong Altered Expression [12]
DUSP5 TTZN92A Strong Biomarker [13]
ENPP2 TTSCIM2 Strong Altered Expression [14]
HMBS TTT0HW3 Strong Biomarker [15]
IGFBP6 TTLAYV8 Strong Altered Expression [16]
KRAS TTM8FR7 Strong Biomarker [17]
NME1 TTDY8JH Strong Biomarker [18]
NRAS TTW2R9X Strong Genetic Variation [19]
OGFR TT6IEYX Strong Biomarker [20]
PCSK2 TT46F0P Strong Biomarker [21]
PRKAR1A TTNAHEX Strong Genetic Variation [9]
RAPGEF3 TTOE7I0 Strong Altered Expression [22]
SDHD TTVH9W8 Strong Genetic Variation [23]
SLC5A5 TTW7HI9 Strong Altered Expression [24]
THRB TTGER3L Strong Biomarker [17]
TIE1 TTT4236 Strong Biomarker [25]
TPCN1 TTODQE2 Strong Biomarker [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DTT(s)
This Disease Is Related to 2 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP2R1 DEBIHM3 Strong Genetic Variation [27]
MINPP1 DE5Q1SP Strong Genetic Variation [28]
------------------------------------------------------------------------------------
This Disease Is Related to 46 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ANO5 OTOW8R6H Limited Altered Expression [29]
BUB3 OTU91HAU Limited Genetic Variation [30]
DIRAS3 OT3XHLQA Limited Biomarker [31]
EVPL OTZIAFEK Limited Genetic Variation [5]
FZD1 OTZATHVS Limited Altered Expression [32]
HTRA3 OTXJ0H4X Limited Altered Expression [33]
INSL3 OT7KUNTE Limited Altered Expression [34]
MT1G OTAV1OCR Limited Altered Expression [35]
MT1M OTVT8PLU Limited Altered Expression [35]
QPRT OT6SKKLL Limited Biomarker [36]
RAB23 OTBAKFBR Limited Altered Expression [35]
ABI3 OTQTDSHP moderate Posttranslational Modification [37]
APLP2 OTTFE53M moderate Biomarker [38]
BCAM OTHZOPSD moderate Altered Expression [39]
CAVIN2 OTFHHDRU moderate Altered Expression [8]
CCL15 OTOGZ85M moderate Biomarker [40]
MRO OT5U38CP moderate Biomarker [41]
NTHL1 OTPQXPT1 moderate Biomarker [42]
OGN OTKP5S4L moderate Altered Expression [8]
PA2G4 OT7IG7HT moderate Altered Expression [43]
RAP1B OTHEIIMM moderate Biomarker [9]
SOSTDC1 OTAKDNSM moderate Biomarker [44]
ST6GAL2 OTXIBF4D moderate Altered Expression [45]
ST6GALNAC2 OT9PBQVT moderate Biomarker [46]
ST6GALNAC4 OTJCJQI7 moderate Biomarker [47]
C1D OTI9PMN1 Strong Biomarker [48]
DIO2 OTGPNSLH Strong Altered Expression [12]
FCGBP OT63T6XQ Strong Altered Expression [49]
GDF10 OTEVXGJ7 Strong Biomarker [50]
IYD OT8BQWTE Strong Altered Expression [51]
MADD OTUFYVGG Strong Biomarker [52]
NIBAN1 OTYOLI12 Strong Biomarker [53]
NUPR1 OT4FU8C0 Strong Biomarker [54]
PAX8 OTRPD9MI Strong Genetic Variation [55]
PROX1 OT68R6IO Strong Biomarker [56]
RASAL1 OTAHUNN7 Strong Genetic Variation [57]
RASSF5 OT6Q41I2 Strong Altered Expression [58]
RPH3AL OT9VFJEL Strong Genetic Variation [59]
SMG1 OTTS3SXE Strong Altered Expression [14]
SPINT1 OT1CLR5L Strong Altered Expression [60]
SRY OT516T6D Strong Biomarker [61]
STT3A OTDPS6AV Strong Biomarker [53]
TAF1 OTDYS5G4 Strong Biomarker [62]
TSHZ1 OTYQ9ECW Strong Biomarker [63]
HCP5 OTV0YRI8 Definitive Biomarker [64]
LIMD2 OTSIFTD8 Definitive Altered Expression [65]
------------------------------------------------------------------------------------
⏷ Show the Full List of 46 DOT(s)

References

1 Lenvatinib FDA Label
2 Circadian clock characteristics are altered in human thyroid malignant nodules.J Clin Endocrinol Metab. 2013 Nov;98(11):4446-56. doi: 10.1210/jc.2013-2568. Epub 2013 Aug 26.
3 Paediatric follicular thyroid carcinoma - indolent cancer with low prevalence of RAS mutations and absence of PAX8-PPARG fusion in a Japanese population.Histopathology. 2017 Nov;71(5):760-768. doi: 10.1111/his.13285. Epub 2017 Aug 24.
4 Downregulated miR-21 mediates matrine-induced apoptosis via the PTEN/Akt signaling pathway in FTC-133 human follicular thyroid cancer cells.Oncol Lett. 2019 Oct;18(4):3553-3560. doi: 10.3892/ol.2019.10693. Epub 2019 Jul 31.
5 Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population.Carcinogenesis. 2016 Jul;37(7):677-684. doi: 10.1093/carcin/bgw047. Epub 2016 Apr 28.
6 Efficacy of lentiviral-mediated transfection of hTSHR in poorly differentiated thyroid carcinoma cell line.Nucl Med Biol. 2013 May;40(4):576-80. doi: 10.1016/j.nucmedbio.2012.12.004.
7 Alteration in the serum concentrations of FGF19, FGFR4 and Klotho in patients with thyroid cancer.Cytokine. 2018 May;105:32-36. doi: 10.1016/j.cyto.2018.02.013. Epub 2018 Feb 10.
8 Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer.Endocrinology. 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013-1028. Epub 2013 Jun 10.
9 Deletion of Rap1b, but not Rap1a or Epac1, Reduces Protein Kinase A-Mediated Thyroid Cancer.Thyroid. 2018 Sep;28(9):1153-1161. doi: 10.1089/thy.2017.0528. Epub 2018 Aug 2.
10 miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4.Oncotarget. 2017 Apr 25;8(17):28028-28041. doi: 10.18632/oncotarget.15885.
11 Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.Am J Pathol. 2005 Jul;167(1):223-31. doi: 10.1016/s0002-9440(10)62967-7.
12 Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma.Clin Endocrinol (Oxf). 2005 Jun;62(6):672-8. doi: 10.1111/j.1365-2265.2005.02277.x.
13 Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.Thorac Cancer. 2020 Feb;11(2):336-345. doi: 10.1111/1759-7714.13270. Epub 2019 Dec 10.
14 Expression, regulation and function of autotaxin in thyroid carcinomas.Int J Cancer. 2004 May 10;109(6):833-8. doi: 10.1002/ijc.20022.
15 Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.Br J Cancer. 2005 Sep 5;93(5):565-70. doi: 10.1038/sj.bjc.6602741.
16 Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes.J Clin Oncol. 2004 Sep 1;22(17):3531-9. doi: 10.1200/JCO.2004.08.127.
17 Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.Clin Cancer Res. 2017 Jan 15;23(2):430-440. doi: 10.1158/1078-0432.CCR-16-0914. Epub 2016 Jul 20.
18 The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma.Cancer Genomics Proteomics. 2014 Jul-Aug;11(4):175-94.
19 Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures.Endocr Pathol. 2018 Mar;29(1):9-14. doi: 10.1007/s12022-017-9491-6.
20 Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.
21 Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination.J Clin Endocrinol Metab. 2005 May;90(5):2512-21. doi: 10.1210/jc.2004-2028. Epub 2005 Feb 15.
22 Elevated aggressive behavior in male mice with thyroid-specific Prkar1a and global Epac1 gene deletion.Horm Behav. 2018 Feb;98:121-129. doi: 10.1016/j.yhbeh.2017.12.012. Epub 2018 Jan 3.
23 Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation.Hum Mol Genet. 2015 Jan 1;24(1):142-53. doi: 10.1093/hmg/ddu425. Epub 2014 Aug 22.
24 Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.Nucl Med Commun. 2011 Jul;32(7):605-10. doi: 10.1097/MNM.0b013e3283463027.
25 Tie-1 tyrosine kinase expression in human thyroid neoplasms.Histopathology. 2004 Apr;44(4):318-22. doi: 10.1111/j.1365-2559.2003.01805.x.
26 Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer.Mol Cell Endocrinol. 2016 Aug 15;431:36-45. doi: 10.1016/j.mce.2016.05.002. Epub 2016 May 3.
27 Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma.Thyroid. 2012 Jul;22(7):709-16. doi: 10.1089/thy.2011.0330. Epub 2012 Jun 12.
28 Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas.J Clin Endocrinol Metab. 2001 Apr;86(4):1801-5. doi: 10.1210/jcem.86.4.7419.
29 Anoctamin5 regulates cell migration and invasion in thyroid cancer.Int J Oncol. 2017 Oct;51(4):1311-1319. doi: 10.3892/ijo.2017.4113. Epub 2017 Sep 1.
30 Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.Anticancer Res. 2008 Jan-Feb;28(1A):139-44.
31 Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.J Clin Endocrinol Metab. 2005 Feb;90(2):1149-55. doi: 10.1210/jc.2004-1447. Epub 2004 Nov 16.
32 Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.J Pathol. 2008 May;215(1):87-96. doi: 10.1002/path.2331.
33 Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors.Oncol Rep. 2012 Nov;28(5):1838-44. doi: 10.3892/or.2012.1988. Epub 2012 Aug 23.
34 Lysosomal acid hydrolases of the cathepsin family are novel targets of INSL3 in human thyroid carcinoma cells.Ann N Y Acad Sci. 2009 Apr;1160:361-6. doi: 10.1111/j.1749-6632.2009.03832.x.
35 A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.Mod Pathol. 2007 Oct;20(10):1095-102. doi: 10.1038/modpathol.3800943. Epub 2007 Jul 27.
36 QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study.BMC Cancer. 2009 Mar 26;9:93. doi: 10.1186/1471-2407-9-93.
37 Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability.Oncotarget. 2016 May 3;7(18):25960-70. doi: 10.18632/oncotarget.8416.
38 APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.Thyroid. 2017 Jan;27(1):59-66. doi: 10.1089/thy.2016.0094. Epub 2016 Nov 30.
39 DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.Blood Cells Mol Dis. 2013 Mar;50(3):161-5. doi: 10.1016/j.bcmd.2012.10.009. Epub 2012 Nov 17.
40 Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15.BMC Cancer. 2016 Feb 15;16:98. doi: 10.1186/s12885-016-2114-7.
41 Vitamin D less-calcemic analog modulates the expression of estrogen receptors, vitamin D receptor and 1-hydroxylase 25-hydroxy vitamin D in human thyroid cancer cell lines.J Steroid Biochem Mol Biol. 2013 Jul;136:80-2. doi: 10.1016/j.jsbmb.2012.09.015. Epub 2012 Oct 8.
42 Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours.J Mol Endocrinol. 2012 Mar 29;48(3):193-202. doi: 10.1530/JME-11-0119. Print 2012 Jun.
43 EBP1 suppresses growth, migration, and invasion of thyroid cancer cells through upregulating RASAL expression.Tumour Biol. 2015 Nov;36(11):8325-31. doi: 10.1007/s13277-015-3523-y. Epub 2015 May 26.
44 SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways.Mol Cell Biochem. 2017 Nov;435(1-2):87-95. doi: 10.1007/s11010-017-3059-0. Epub 2017 May 27.
45 LncRNA HCP5 promotes follicular thyroid carcinoma progression via miRNAs sponge.Cell Death Dis. 2018 Mar 7;9(3):372. doi: 10.1038/s41419-018-0382-7.
46 ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-B signaling pathway in follicular thyroid carcinoma.Oncol Rep. 2016 Apr;35(4):2131-40. doi: 10.3892/or.2016.4590. Epub 2016 Jan 22.
47 miR-4299 mediates the invasive properties and tumorigenicity of human follicular thyroid carcinoma by targeting ST6GALNAC4.IUBMB Life. 2016 Feb;68(2):136-44. doi: 10.1002/iub.1467. Epub 2015 Dec 30.
48 Identification of a novel Rac3-interacting protein C1D.Int J Mol Med. 1998 Apr;1(4):665-70. doi: 10.3892/ijmm.1.4.665.
49 Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas.J Endocrinol. 2002 Sep;174(3):517-24. doi: 10.1677/joe.0.1740517.
50 Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis.Cancer Res. 2003 Jun 1;63(11):2864-71.
51 Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
52 Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.J Clin Endocrinol Metab. 2009 Apr;94(4):1467-71. doi: 10.1210/jc.2008-2378. Epub 2009 Feb 3.
53 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.J Clin Invest. 2004 Apr;113(8):1234-42. doi: 10.1172/JCI19617.
54 High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid.Pathology. 2006 Dec;38(6):545-7. doi: 10.1080/00313020601024094.
55 Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.Oncotarget. 2017 Jan 24;8(4):5761-5773. doi: 10.18632/oncotarget.14050.
56 Transcription Factor Prospero Homeobox 1 (PROX1) as a Potential Angiogenic Regulator of Follicular Thyroid Cancer Dissemination.Int J Mol Sci. 2019 Nov 10;20(22):5619. doi: 10.3390/ijms20225619.
57 Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.J Clin Endocrinol Metab. 2014 Jul;99(7):E1316-21. doi: 10.1210/jc.2014-1225. Epub 2014 Apr 8.
58 The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.J Clin Endocrinol Metab. 2006 Mar;91(3):1143-9. doi: 10.1210/jc.2005-1372. Epub 2005 Dec 13.
59 Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus.Genomics. 1999 Jul 1;59(1):97-101. doi: 10.1006/geno.1999.5864.
60 Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.Histochem Cell Biol. 2018 Jun;149(6):635-644. doi: 10.1007/s00418-018-1660-2. Epub 2018 Mar 12.
61 Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.PLoS One. 2019 Jan 17;14(1):e0210106. doi: 10.1371/journal.pone.0210106. eCollection 2019.
62 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5. doi: 10.1210/jcem.86.7.7621.
63 N-ras mutation of thyroid tumor with special reference to the follicular type.Pathol Int. 1995 Jan;45(1):45-50. doi: 10.1111/j.1440-1827.1995.tb03378.x.
64 Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.Biomed Pharmacother. 2019 Aug;116:108966. doi: 10.1016/j.biopha.2019.108966. Epub 2019 May 16.
65 LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.Endocr Pathol. 2018 Sep;29(3):222-230. doi: 10.1007/s12022-018-9526-7.